Alnylam, GSK Strike $1 B RNAi Development and Commercialization Pact for China
Alnylam granted GSK exclusive rights to develop and commercialize its RNAi therapies in Greater China under a deal valued at up to $1 billion including an unspecified upfront payment and development milestones. Alnylam retains eligibility for tiered royalties on product sales and additional milestone payments tied to clinical and sales targets.
1. Deal Overview
Alnylam and GSK have entered a strategic collaboration granting GSK exclusive rights to develop and commercialize Alnylam’s RNA interference therapies in Greater China, covering discovery through late-stage clinical programs.
2. Financial Terms and Milestones
The agreement carries a potential value of up to $1 billion, composed of an upfront fee, development and regulatory milestone payments, commercial sales-based milestones and tiered royalties on net sales in the region.
3. Program Scope
Initial scope includes multiple candidates from Alnylam’s RNAi pipeline, with provisions to expand into additional targets, leveraging GSK’s development capabilities and regulatory infrastructure across mainland China, Hong Kong, Macau and Taiwan.
4. Strategic Implications
This partnership bolsters Alnylam’s Asia-Pacific presence without adding regional operating costs, delivers a non-dilutive funding infusion and accelerates access to a large emerging market that could drive near-term revenue growth.